Date: 2016-07-12
Type of information: Nomination
Compound:
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 12, 2016, Amicus Therapeutics has appointed Andrew E. Mulberg, MD, FAAP, CPI as Vice President, Regulatory Strategy. He will be responsible for directing global regulatory strategies for all Amicus programs to bring multiple therapies to patients with rare and devastating diseases. Dr. Mulberg is a pediatric gastroenterologist who has spent the past 6 years working at the FDA, most recently as Deputy Director of the Division of Gastroenterology and Inborn Errors Products. Dr. Mulberg will serve as a member of the executive team reporting to Jay A. Barth, M.D., Chief Medical Officer. In addition to Dr. Mulberg's FDA experience, he previously held various roles of increasing responsibility within global drug development and medical affairs at leading pharmaceutical companies, including Johnson & Johnson, where he successfully led multiple products through clinical development to regulatory approvals. Dr. Mulberg received his B.A. from Columbia University and his M.D. from the Mount Sinai School of Medicine. From 1993-2010, Andrew served as Attending Physician in Gastroenterology and Hepatology at Children's Hospital of Philadelphia. He currently serves as Adjunct Professor of Pediatrics at the University of Maryland School of Medicine, Adjunct Associate Professor of Pediatrics in the University of Pennsylvania School of Medicine and Associate Professor of Pharmacy at the University of the Sciences in Philadelphia. He is also a member of numerous medical organizations including Alpha Omega Alpha Honor Medical Society, American Gastroenterological Association and the North American Society for Pediatric Gastroenterology and Nutrition.
Financial terms:
Latest news:
